drugset / Trial / NCT03812510

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03812510

Phase 3 Completed 426 enrolled Aclaris Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts

Timeline

Start
2019-02-07
Primary completion
2019-11-27
Completion
2019-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrogen Peroxide Small molecule 45 % Topical

Indications